natgillin/translations-raw huggingface dataset:
In a pooled analysis of the data from 13 studies, the overall incidences of cardiovascular death, non fatal myocardial infarction and non-fatal stroke were comparable in patients treated with 25 mg alogliptin, active control or placebo. 
Združena analiza podatkov iz 13 študij kaže, da je bila celotna pojavnost umrljivosti zaradi kardiovaskularnih vzrokov in pojavnost neusodnega miokardnega infarkta ter neusodne možganske kapi pri bolnikih, ki so se zdravili z alogliptinom v odmerku 25 mg, s kontrolnim zdravilom ali placebom, primerljiva.
Table 2: Change in HbA1c (%) from baseline with alogliptin 25 mg at Week 26 by placebo-controlled study (FAS, LOCF) 
Preglednica 2: Sprememba vrednosti HbA1c (%) v 26. tednu v primerjavi z izhodiščem pri uporabi alogliptina v odmerku 25 mg v s placebom nadzorovani študiji (FAS, LOCF) Študija
There was no tumourigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months. 
Hiperplazije sečnega mehurja niso opazili pri psih ali opicah, ki so pioglitazon prejemale do 12 mesecev.
Similar changes were seen in metformin- (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea- and insulin- (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative-controlled studies with pioglitazone. 
Podobne spremembe so opazili v s primerjalnim zdravilom nadzorovanih študij ah pioglitazona pri bolnikih, ki so se zdravili z metforminom (relativno zmanjšanje hemoglobina za 3-4 % in hematokrita za 3,6-4,1 %), v manjši meri pa tudi pri bolnikih, ki so se zdravili s sulfonilsečnino in z insulinom (relativno zmanjšanje hemoglobina za 1-2 % in hematokrita za
Add-on combination therapy studies Alogliptin 25 mg once daily with pioglitazone + metformin vs titrating pioglitazone + metformin 
Študije dodatnega kombiniranega zdravljenja Alogliptin 25 mg enkrat na dan s pioglitazonom + metforminom v primerjavi s titracijo pioglitazona + metformina
Incresync should not be used during pregnancy or breast-feeding. 
Zdravila Incresync med nosečnostjo ali dojenjem ne smete uporabljati.
The information provided is based on a total of 3,504 patients with type 2 diabetes mellitus, including 1,908 patients treated with alogliptin and pioglitazone, who participated in 4 phase 3 double-blind, placebo- or active-controlled clinical studies. 
Navedeni podatki temeljijo na skupno 3.504 bolnikih s sladkorno boleznijo tipa 2, vključno s 1.908 bolniki, zdravljenimi z alogliptinom in s pioglitazonom, ki so bili vključeni v 4 dvojno slepe, s placebom ali z zdravilno učinkovino nadzorovane klinične študije 3. faze.
What Incresync contains - The active substances are alogliptin and pioglitazone. 
Kaj vsebuje zdravilo Incresync - Učinkovini sta alogliptin in pioglitazon.
The following section outlines the interactions observed with the individual components of Incresync (alogliptin/pioglitazone) as reported in their respective Summary of Product Characteristics. 
V nadaljevanju so navedene interakcije, ki so bile opažene pri posameznih sestavinah zdravila Incresync (alogliptin/pioglitazon), kot so navedena v njunih povzetkih glavnih značilnosti zdravila.
Placental transfer of alogliptin occurs in rats. 
Alogliptin pri podganah prehaja preko placente.
In controlled clinical studies, the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. 
V nadzorovanih kliničnih študijah je bila pojavnost srčnega popuščanja pri bolnikih, zdravljenih s pioglitazonom, enaka kot pri bolnikih, zdravljenih s placebom, z metforminom in s sulfonilsečnino, vendar pa je bila pri kombiniranem zdravljenju z insulinom večja.
MACE Reported in cardiovascular outcomes study Number of Patients (%) 
Poročila o MACE v študiji kardiovaskularnih izidov
In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients ≥ 65 years old treated with 25 mg alogliptin (3.8%) to that in patients < 65 years old (3.6%). 
V združeni analizi podatkov iz 12 študij je bila celotna pojavnost vseh epizod hipoglikemije pri bolnikih, starih 65 let ali starejših, ki so se zdravili s alogliptinom v odmerku 25 mg (3,8 %), podobna kot pri bolnikih, mlajših od 65 let (3,6 %).
The no-observed-adverse-effect level (NOAEL) in the repeated dose toxicity studies in rats and dogs up to 26- and 39-weeks in duration, respectively, produced exposure margins that were approximately 147- and 227-fold, respectively, the exposure in humans at the recommended daily dose of 25 mg alogliptin. 
Pri študijah toksičnosti pri ponavljajočih se odmerkih, ki so pri podganah trajale do 26 tednov, pri psih pa do 39 tednov, je bila mejna vrednost izpostavljenosti brez opaženih neželenih učinkov (NOAEL; “no-observed-adverse-effect level”) pri podganah 147-krat pri psih pa 227-krat večja od izpostavljenosti človeka pri priporočenem 25 mg odmerku alogliptina.
Based on mean dialysate concentrations, approximately 7% of the active substance was removed during a 3-hour haemodialysis session. 
Na osnovi povprečnih koncentracij dializata se je med 3-urnim postopkom dialize odstranilo približno 7 % učinkovine.)
The following section outlines the pharmacokinetic properties of the individual components of Incresync (alogliptin/pioglitazone) as reported in their respective Summary of Product Characteristics. 
V nadaljevanju so navedene farmakokinetične lastnosti posameznih učinkovin zdravila Incresync (alogliptin/pioglitazon), kot so navedene v njunih povzetkih glavnih značilnosti zdravila.
Caution should be exercised when alogliptin is used in combination with metformin and a thiazolidinedione as an increased risk of hypoglycaemia has been observed with this triple therapy (see section 4.4). 
Če se alogliptin uporablja v kombinaciji z metforminom in s tiazolidindionom je potrebna previdnost, saj so pri tem trotirnem zdravljenju poročali o večjem tveganju za pojav hipoglikemije (glejte poglavje 4.4).
There are no data from the use of alogliptin in pregnant women. 
Podatkov o uporabi alogliptina pri nosečnicah ni.
Pioglitazone and all active metabolites are extensively bound to plasma protein (> 99%). 
Pioglitazon in vsi njegovi aktivni presnovki se v velikem obsegu vežejo na plazemske proteine
Hypoglycaemia may occur in combination with sulphonylureas or insulin. 
V kombinaciji s sulfonilsečninami ali z insulinom se lahko pojavi hipoglikemija.
In vitro studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. 
Študije in vitro niso pokazale, da bi pioglitazon zaviral kateri koli podtip citokroma P450.
Excipient(s) with known effect Each tablet contains 121 mg of lactose (as monohydrate). 
Pomožne snovi z znanim učinkom Ena tableta vsebuje 121 mg laktoze (v obliki monohidrata).
Administration of 25 mg alogliptin to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once-daily dosing. 
Pri bolnikih s sladkorno boleznijo tipa 2 je bila največja inhibicija DPP-4 dosežena v 1 do 2 urah po uporabi alogliptina v odmerku 25 mg in je tako pri enkratnem odmerku 25 mg kot tudi pri 14-dnevnem odmerjanju enkrat na dan presegla 93 %.
For patients inadequately controlled on dual therapy with pioglitazone and a maximally tolerated dose of metformin, the dose of metformin should be maintained, and Incresync administered concomitantly. 
Pri bolnikih z neustrezno urejeno sladkorno boleznijo pri kombiniranem zdravljenju s pioglitazonom in z metforminom v največjem odmerku, ki ga prenašajo, je treba odmerek metformina ohraniti, zdravljenje z zdravilom Incresync pa uvesti sočasno.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced postprandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. 
V 20-tedenski študiji je pioglitazon znižal raven trigliceridov na tešče, pa tudi hipertrigliceridemijo po obroku, in sicer tako preko vpliva na absorpcijo trigliceridov kot njihovo sintezo v jetrih.
Pharmacotherapeutic group: Drugs used in diabetes; combinations of oral blood glucose lowering drugs. 
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, kombinacije peroralnih antidiabetikov
Type 2 diabetes is also called non-insulin-dependent diabetes mellitus or NIDDM. 
Sladkorno bolezen tipa 2 imenujemo tudi od insulina neodvisna sladkorna bolezen.
Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. 
Zlome so opazili pri 2,6 % žensk, ki so se zdravile s pioglitazonom, in pri 1,7 % žensk, ki so prejemale primerjalno zdravilo.
Excipient(s) with known effect Each tablet contains 105 mg of lactose (as monohydrate). 
Pomožne snovi z znanim učinkom Ena tableta vsebuje 105 mg laktoze (v obliki monohidrata).
In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant (p<0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC(0-8) change from baseline compared to placebo. 
Razen tega je alogliptin v odmerku 25 mg, sam in v kombinaciji s 30 mg pioglitazona, v 16. tednu povzročil statistično pomembno (p<0,001) zmanjšanje skupne vrednosti trigliceridov, izmerjene s postprandialno inkrementalno AUC(0-8) spremembo glede na izhodiščno vrednost v primerjavi s placebom.
Co-administration of pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea. 
Kaže da sočasna uporaba pioglitazona in sulfonilsečnin ne vpliva na farmakokinetiko sulfonilsečnine.
The significant reductions in HbA1c observed with 25 mg alogliptin plus 30 mg pioglitazone and metformin were consistent over the entire 52-week treatment period compared to 45 mg pioglitazone and metformin (p<0.001 at all time points). 
Pomembna znižanja vrednosti HbA1c, ki so bila opažena pri uporabi alogliptina v odmerku 25 mg v kombinaciji s 30 mg pioglitazona in z metforminom, so bila konsistentna skozi celotno 52-tedensko obdobje zdravljenja v primerjavi z zdravljenjem s 45 mg pioglitazona in z metforminom (p<0,001 v vseh časovnih točkah).
The symptoms may include: a rash, hives, swallowing or breathing problems, swelling of your lips, face, throat or tongue and feeling faint. 
Simptomi lahko vključujejo: izpuščaj, koprivnico, težave s požiranjem ali z dihanjem, otekanje ustnic, obraza, žrela ali jezika in omedlevico.
The average renal clearance of alogliptin (170 mL/min) was greater than the average estimated glomerular filtration rate (approx. 120 mL/min), suggesting some active renal excretion. 
Povprečni ledvični očistek alogliptina (170 ml/min) je večji od povprečne ocenjene stopnje glomerulne filtracije (pribl.
Skin and subcutaneous tissue disorders pruritus common common rash common exfoliative skin conditions including StevensJohnson syndrome not known erythema multiforme not known angioedema not known urticaria not known 
Bolezni jeter, žolčnika in žolčevodov okvara delovanja jeter, vključno z odpovedjo jeter neznana Bolezni kože in podkožja pruritus pogosti pogosti izpuščaj pogosti eksfoliativne bolezni kože, vključno s stevens-johnsonovim sindromom neznana multiformni eritem neznana angioedem neznana urtikarija neznana
Heart failure has been reported rarely with marketing use of pioglitazone, but more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
Med spremljanjem pioglitazona v obdobju trženja so o primerih srčnega popuščanja poročali redko, vendar pogosteje, če je bil pioglitazon uporabljen v kombinaciji z insulinom ali pri bolnikih s srčnim popuščanjem v anamnezi.
The co-administration of alogliptin and pioglitazone has been studied as dual therapy in patients initially treated with pioglitazone alone (with or without metformin or a sulphonylurea) and as add-on therapy to metformin. 
Sočasna uporaba alogliptina in pioglitazona je bila raziskana v okviru kombiniranega zdravljenja pri bolnikih, ki so se najprej zdravili samo s pioglitazonom (z metforminom ali s sulfonilsečnino ali brez), in v okviru dodatka k zdravljenju z metforminom.
Results from clinical interaction studies also demonstrate that there are no clinically relevant effects of gemfibrozil (a CYP2C8/9 inhibitor), fluconazole (a CYP2C9 inhibitor), ketoconazole (a CYP3A4 inhibitor), cyclosporine (a p-glycoprotein inhibitor), voglibose (an alpha-glucosidase inhibitor), digoxin, metformin, cimetidine, pioglitazone or atorvastatin on the pharmacokinetics of alogliptin. 
Rezultati kliničnih študij medsebojnega delovanja kažejo tudi, da gemfibrozil (zaviralec CYP2C8/9), flukonazol (zaviralec CYP2C9), ketokonazol (zaviralec CYP3A4), ciklosporin (zaviralec p-glikoproteina), vogliboza (zaviralec glukozidaze alfa), digoksin, metformin, cimetidin, pioglitazon ali atorvastatin nimajo klinično pomembnih učinkov na farmakokinetiko alogliptina.
There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. 
Med zdravljenjem s pioglitazonom so poročali o majhnem zmanjšanju povprečne koncentracije hemoglobina (relativno zmanjšanje za 4 %) in hematokrita (relativno zmanjšanje za 4,1 %), kar se sklada s hemodilucijo.
In most clinical studies, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo with small, but not clinically significant, increases in LDL-cholesterol levels. 
V večini kliničnih študij so v primerjavi s placebom opažali zmanjšanje celotne koncentracije trigliceridov in prostih maščobnih kislin v plazmi ter povečanje koncentracije holesterola HDL, z majhnimi, a klinično nepomembnimi povečanji koncentracije holesterola LDL.
There were 703 patients who experienced an event within the secondary MACE composite endpoint (first event of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and urgent revascularization due to unstable angina). 
O dogodku iz sklopa sekundarnega sestavljenega opazovanega dogodka MACE (prvi dogodek kardiovaskularne smrti, neusodnega miokardnega infarkta, neusodne možganske kapi in urgentne revaskularizacije zaradi nestabilne angine pektoris) so poročali pri 703 bolnikih.
The studies included 1,269 patients with mild renal impairment and 161 patients with moderate renal impairment treated with alogliptin/pioglitazone. 
V študijah se je z alogliptinom/pioglitazonom zdravilo 1.269 bolnikov z blago okvaro ledvic in 161 bolnikov z zmerno okvaro ledvic.
Musculoskeletal and connective tissues disorders myalgia common fracture bone common 
Bolezni mišično-skeletnega sistema in vezivnega tkiva mialgija pogosti zlomi kosti pogosti
Adults (≥ 18 years old) The dose should be individualised on the basis of the patient's current treatment regimen 
Odmerek zdravila je treba določiti pri vsakem bolniku posebej na osnovi bolnikovega trenutnega režima zdravljenja.
Gastrointestinal disorders abdominal pain common common gastroesophageal reflux disease common diarrhoea common dyspepsia common nausea common acute pancreatitis not known 
Bolezni prebavil bolečina v trebuhu pogosti pogosti gastroezofagealni refluks pogosti diareja pogosti dispepsija pogosti navzea pogosti akutni pankreatitis neznana
Repeated dosing does not result in accumulation of the compound or metabolites. 
Pri ponavljajočem se odmerjanju ne pride do kopičenja učinkovine ali presnovkov.
Both 25 mg alogliptin alone and in combination with 30 mg pioglitazone demonstrated significant decreases in postprandial glucose and postprandial glucagon whilst significantly increasing postprandial active GLP-1 levels at Week 16 compared to placebo (p<0.05). 
Tako pri uporabi samega alogliptina v odmerku 25 mg kot tudi v kombinaciji s 30 mg pioglitazona so v 16. tednu ugotovili pomembno zmanjšanje postprandialne vrednosti glukoze in glukagona ob pomembnem povečanju postprandialnih vrednosti aktivnega GLP-1 v primerjavi s placebom (p<0,05).
In studies performed with the individual active substances, both alogliptin and pioglitazone were excreted in the milk of lactating rats. 
Pri študijah, izvedenih s posameznima zdravilnima učinkovinama, sta se tako alogliptin kot pioglitazon izločala v mleko doječih podgan.
The risk of fractures should be considered in the long-term care of patients treated with Incresync (see section 4.8). 
Pri dolgoročnem zdravljenju z zdravilom Incresync, je pri bolnikih treba upoštevati tveganje za zlome (glejte poglavje 4.8).
General disorders and administration site conditions oedema peripheral common weight increased common 
Splošne težave in spremembe na mestu aplikacije periferni edem pogosti povečanje telesne mase pogosti
No adverse effects on fertility were observed in animal studies conducted with alogliptin (see section 5.3). 
Pri študijah z alogliptinom pri živalih niso opazili neželenih učinkov na plodnost (glejte poglavje 5.3).
This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy, thereby reducing the availability of metabolic substrates for foetal growth. 
To je mogoče pripisati vplivu pioglitazona na zmanjšanje hiperinsulinemije pri samici in večji odpornosti proti insulinu med brejostjo, zaradi česar se zmanjša dostopnost presnovnih substratov za rast plodu.
LOCF = last observation carried forward * Non inferiority and superiority statistically demonstrated † Least squares means adjusted for prior antihyperglycaemic therapy status and baseline values 
PPS = bolniki po protokolu (“per protocol set”) LOCF = prenos zadnjih opaženih vrednosti naprej (“last observation carried forward”) * Ne-inferiornost in superiornost statistično dokazana † Srednja vrednost najmanjših kvadratov, prilagojena gleda na predhodno antihiperglikemično zdravljenje in vrednosti v izhodišču
- if you suffer from heart disease or fluid retention. 
• če imate bolezen srca ali težave z zastajanjem tekočine v telesu.
Mean baseline HbA1c (%) (SD) 
Povprečna vrednost HbA1c v izhodišču (%) (SD)
Not known: - Visual disturbances (caused by a condition called macular oedema). 
• Motnje vida (ki so posledica edema rumene pege).
For the different dose regimens Incresync is available in strengths of 25 mg/30 mg, 25 mg/45 mg, 12.5 mg/30 mg and 12.5 mg/45 mg film-coated tablets. 
Za različne režime odmerjanja je zdravilo Incresync na voljo v različnih jakostih, in sicer v obliki 25 mg/30 mg, 25 mg/45 mg, 12,5 mg/30 mg in 12,5 mg/45 mg filmsko obloženih tablet.
In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively. 
V študiji kardiovaskularnih izidov je delež poročil o pankreatitisu pri bolnikih, ki so se zdravili z alogliptinom znašal 3, pri bolnikih, ki so prejemali placebo, pa 2 dogodka na 1.000 bolnikov-let.
No alogliptin-related effects were observed in juvenile rats following repeat-dose administration for 4 and 8 weeks. 
Pri mladih podganah pri ponavljajočem se odmerjanju v obdobju 4 in 8 tednov niso opazili vplivov, povezanih z uporabo alogliptina.
The pioglitazone dose may need to be increased when rifampicin is concomitantly administered. 
Pri sočasni uporabi rifampicina bo odmerek pioglitazona morda treba povečati.
Administration of Incresync with food resulted in no change in overall exposure to alogliptin or pioglitazone. 
Pri uporabi zdravila Incresync skupaj s hrano se skupna izpostavljenost alogliptinu ali pioglitazonu ni spremenila.
A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. 
Pri bolnikih, predvsem ženskah, ki so jemali samo pioglitazon, so opazili večje število zlomov kosti.
Alogliptin may, therefore, be administered with or without food. 
Alogliptin se tako lahko jemlje skupaj s hrano ali brez nje.
- if you have had a serious allergic reaction to any other similar medicines that you take to control your blood sugar. 
• če ste za uravnavanje vrednosti krvnega sladkorja že jemali druga podobna zdravila in se je pri tem pojavila huda alergijska reakcija.
As there is a need for dose adjustment of alogliptin in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis, appropriate assessment of renal function is recommended prior to initiation of Incresync and periodically thereafter (see section 4.2). 
Pri bolnikih z zmerno ali s hudo okvaro ledvic in bolnikih s končno ledvično odpovedjo, ki potrebujejo zdravljenje z dializo, je treba odmerek alogliptina prilagoditi, zato pred uvedbo zdravljenja z zdravilom Incresync in v rednih časovnih presledkih med zdravljenjem priporočamo izvedbo ustreznih preiskav za oceno delovanja ledvic (glejte poglavje 4.2).
Although fertility was not affected, a slight, statistical increase in the number of abnormal sperm was observed in males at an exposure far above the human exposure at the recommended dose. 
Čeprav vpliva na plodnost ni bilo, so pri samcih pri izpostavljenosti, ki je bila veliko večja od izpostavljenosti človeka pri priporočenem odmerku, opazili rahel statističen porast števila abnormalnih spermijev.
Significantly more patients receiving 25 mg alogliptin (49.2%) achieved target HbA1c levels of ≤ 7.0% compared to those receiving placebo (34.0%) at Week 26 (p=0.004). 
V 26. tednu je ciljne vrednosti HbA1c ≤ 7,0 % doseglo pomembno več bolnikov, ki so prejemali alogliptin v odmerku 25 mg (49,2 %), v primerjavi z bolniki, ki so prejemali placebo (34,0 %) (p=0,004).
If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up for a forgotten dose. 
Če ste pozabili vzeti odmerek, ga vzemite takoj, ko se spomnite.
In toxicology studies, plasma volume expansion with haemodilution, anaemia and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs and monkeys. 
V toksikoloških študijah so pri večkratnem odmerjanju pri miših, podganah, psih in opicah dosledno opažali povečanje plazemskega volumna s hemodilucijo, anemijo in reverzibilno ekscentrično hipertrofijo srca.
Following oral administration, pioglitazone is rapidly absorbed and peak serum concentrations of unchanged pioglitazone are usually achieved 2 hours after administration. 
Največje koncentracije nespremenjenega pioglitazona v serumu so običajno dosežene 2 uri po uporabi.
What Incresync is used for 
Za kaj uporabljamo zdravilo Incresync
Therefore, no dose adjustment of alogliptin is necessary for patients with mild to moderate hepatic impairment (Child-Pugh scores of 5 to 9). 
Obseg teh zmanjšanj ni klinično pomemben, zato pri bolnikih z blago do zmerno okvaro jeter (ocena po Child-Pugh-u od 5 do 9) odmerka alogliptina ni treba prilagajati.
mood change or feeling confused. 
• Zamegljen ali popačen vid.
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and toxicology. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti in toksičnosti ne kažejo posebnega tveganja za človeka.
The results of bioequivalence studies in healthy subjects demonstrated that Incresync film-coated tablets are bioequivalent to the corresponding doses of alogliptin and pioglitazone co-administered as separate tablets. 
Rezultati študij bioekvivalence pri zdravih osebah so pokazali, da so filmsko obložene tablete zdravila Incresync bioekvivalentne ustreznim odmerkom alogliptina in pioglitazona, sočasno uporabljenim v obliki ločenih tablet.
In addition, mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p<0.001). 
Poleg tega je bila povprečna sprememba vrednosti glukoze v plazmi na tešče glede na izhodiščno vrednost v 52. tednu pri uporabi alogliptina v odmerku 25 mg v kombinaciji s 30 mg pioglitazona in z metforminom pomembno večja od tiste pri uporabi 45 mg pioglitazona in metformina (p<0,001).